title: How to revive breakthrough innovation in the pharmaceutical industry.
abstract: Over the past 20 years, pharmaceutical companies have implemented conservative management practices to improve the predictability of therapeutics discovery and success rates of drug candidates. This approach has often yielded compounds that are only marginally better than existing therapies, yet require larger, longer, and more complex trials. To fund them, companies have shifted resources away from drug discovery to late clinical development; this has hurt innovation and amplified the crisis brought by the expiration of patents on many best-selling drugs. Here, we argue that more breakthrough therapeutics will reach patients only if the industry ceases to pursue "safe" incremental innovation, re-engages in high-risk discovery research, and adopts collaborative innovation models that allow sharing of knowledge and costs among collaborators.
authors.affiliation: InnoThink Center for Research in Biomedical Innovation, Indianapolis, IN 46228-1422, USA. bhmunos@stanfordalumni.org
authors.forename: Bernard H
authors.initials: BH
authors.lastname: Munos
authors.forename: William W
authors.initials: WW
authors.lastname: Chin
mesh_terms: D055808:Drug Discovery; D004345:Drug Industry / Q000191:economics* / Q000458:organization & administration / Q000639:trends*; D006801:Humans; D004364:Pharmaceutical Preparations; D012106:Research / Q000191:economics* / Q000639:trends*; D012307:Risk Factors
chemical_list: D004364:Pharmaceutical Preparations